CIViC Compass
Research use only — not FDA-cleared, not medical advice. Always consult FDA-approved labeling and a qualified clinician.

CIViC Evidence Items

34 evidence items indexed

Evidence Level Distribution

CIViC evidence levels reflect study design quality, from A (strongest) to E (weakest).

AValidated — meta-analysis, systematic review, or major guideline
BClinical — prospective trial or retrospective cohort study
CCase study — single case report or small case series
DPreclinical — in vitro or animal model data
EInferential — computational prediction or biological rationale

Gene × Evidence Type

Count of CIViC evidence items per gene and evidence type category. Hover a column header for the type definition.

PredictiveDiagnosticPrognosticFunctionalPredispos.Oncogenic
BCR::ABL132311
BRAF18642621
EGFR2481232
EML4::ALK64
ERBB21422
FLT355221
KIT10237
KRAS1594244
PIK3CA156164
PTEN5313121
TP5352401002
VHL52363515
Predictive:Links a variant to treatment response or resistance
Diagnostic:Supports or refutes a specific disease diagnosis
Prognostic:Informs disease progression or clinical outcome
Functional:Characterises the biological effect of a variant
Predisposing:Germline variant associated with cancer predisposition
Oncogenic:Characterises the variant's role in oncogenesis
Clear
LevelGeneVariantTypeDirectionSignificanceDiseaseDrugsSource
DFGFR3R248CFunctionalSupportsGain of FunctionNaski et al., 1996
DFGFR3S249CPredictiveSupportsSensitivity/ResponseCancerInfigratinib,PD173074Chandrani et al., 2017
AFGFR3MutationPredictiveSupportsSensitivity/ResponseTransitional Cell CarcinomaErdafitinibLoriot et al., 2019
DFGFR3S249COncogenicSupportsOncogenicityBladder Urothelial CarcinomaBernard-Pierrot et al., 2006
DFGFR3A391EFunctionalSupportsGain of FunctionSarabipour et al., 2016
BFGFR3Y373CDiagnosticSupportsPositiveBladder CarcinomaBodoor et al., 2010
DFGFR3OverexpressionPredictiveSupportsSensitivity/ResponseBladder CarcinomaTyrosine Kinase Inhibitor SU5402,Dovitinib,PD173074Lamont et al., 2011
BFGFR3MutationPredictiveSupportsSensitivity/ResponseBladder CarcinomaInfigratinibNogova et al., 2017
BFGFR3MutationPredictiveSupportsSensitivity/ResponseUrinary Bladder CancerCisplatin,GemcitabineYang et al., 2018
DFGFR3S249COncogenicSupportsOncogenicityLung Squamous Cell CarcinomaLiao et al., 2013
CFGFR3AmplificationPredictiveDoes Not SupportSensitivity/ResponseBreast CancerPazopanibWheler et al., 2016
DFGFR3R248CPredictiveDoes Not SupportResistanceCancerR3MabQing et al., 2009
DFGFR3S249CPredictiveSupportsResistanceTransitional Cell CarcinomaCisplatinXie et al., 2019
DFGFR3S249CFunctionalSupportsGain of FunctionDel Piccolo et al., 2015
DFGFR3S249COncogenicSupportsOncogenicityTransitional Cell Carcinomadi Martino et al., 2009
DFGFR3Y373COncogenicSupportsOncogenicityUrinary Bladder CancerBernard-Pierrot et al., 2006
DFGFR3OverexpressionPredictiveSupportsSensitivity/ResponseCancerR3MabQing et al., 2009
DFGFR3G370CPredictiveDoes Not SupportResistanceCancerR3MabQing et al., 2009
DFGFR3Y373CPredictiveDoes Not SupportResistanceCancerR3MabQing et al., 2009
DFGFR3K650EPredictiveDoes Not SupportResistanceCancerR3MabQing et al., 2009
DFGFR3K650EFunctionalSupportsGain of FunctionWebster et al., 1996
DFGFR3K650DFunctionalSupportsGain of FunctionWebster et al., 1996
DFGFR3K650EFunctionalSupportsGain of FunctionNowroozi et al., 2005
DFGFR3G697COncogenicDoes Not SupportOncogenicityCancerPatani et al., 2016
CFGFR3S249CPredictiveSupportsSensitivity/ResponseTransitional Cell CarcinomaPazopanibPalma et al., 2015
DFGFR3V555MPredictiveSupportsResistanceMyeloid NeoplasmPD173074,Fexagratinib,AZ12908010Chell et al., 2013
DFGFR3K650NFunctionalSupportsGain of FunctionBellus et al., 2000
DFGFR3K650QFunctionalSupportsGain of FunctionBellus et al., 2000
DFGFR3K650MFunctionalSupportsGain of FunctionBellus et al., 2000
DFGFR3K650TFunctionalSupportsGain of FunctionBellus et al., 2000
DFGFR3K650QFunctionalSupportsGain of FunctionWebster et al., 1996
DFGFR3K650LFunctionalSupportsGain of FunctionWebster et al., 1996
DFGFR3G380RFunctionalSupportsGain of FunctionWebster et al., 1996
DFGFR3K650EFunctionalSupportsGain of FunctionBellus et al., 2000